Open access
Aug 2026
In silico discovery of RIOK3 inhibitors against pancreatic ductal adenocarcinoma using homology modelling, molecular docking, molecular dynamics simulations, ADMET prediction, and MTT assay
RIOK3 is identified as a promising therapeutic target for PDAC, with Venetoclax, Conivaptan, Drospirenone, and Irinotecan as repurposable candidates for further research.
Kawthar Alhussieni, R. Othman, Tamilanban Thamaraikani et al.
· Journal of Computer-Aided Mo... · 1 citation